Lumos PHARMA, INC. Management Discussion and Analysis of Financial Condition and Results of Operations (Form 10-Q)

Sub Levels

The following discussion and analysis should be read in conjunction with the
unaudited condensed consolidated financial statements and notes thereto included
in Part I, Item 1 of this quarterly report on Form 10­Q for the quarter ended
March 31, 2023 (this "Quarterly Report"). This Quarterly Report contains
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995, such
statements are subject to the "safe harbor" created by those sections and
involve risks and uncertainties. Forward-looking statements are based on our
management's beliefs and assumptions and on information available to our
management as of the date hereof. As a result of many factors, such as those set
forth under "Item 1A. Risk Factors" included in our 2022 Annual Report and Part
II, "Item 1A. Risk Factors" in this Quarterly Report, our actual results may
differ materially from those anticipated in these forward-looking statements,
accordingly, you should not place undue reliance on these forward-looking
statements. Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons actual results
could differ materially from those anticipated in these forward-looking
statements, even if new information becomes available in the future. Such
factors may be amplified by the COVID-19 pandemic and its potential impact on
our business and the global economy.


Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. References in
this Quarterly Report to "us," "we," "our," the "Company," or "Lumos" are to
Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal
executive offices located in Austin, Texas and additional executive and
administrative offices located in Ames, Iowa, we are engaged in advancing our
clinical program and focused on identifying, acquiring, developing, and
commercializing novel products and new therapies for people with rare diseases
on a global level, for which there is currently a significant unmet need for
safe and effective therapies. Our common stock is listed on the Nasdaq Global
Market ("Nasdaq") and trades under the ticker symbol "LUMO."

We have focused our efforts on the development of our sole product candidate,
growth hormone secretagogue ibutamoren ("LUM-201"), a potential oral therapy for
idiopathic pediatric growth hormone deficiency ("PGHD") and other rare endocrine

PGHD is a rare endocrine disorder occurring in approximately one in 3,500
persons aged birth to 17 years. Causes of PGHD can be congenital (children are
born with the condition), acquired (radiation therapy for a brain tumor, head
injuries or other causes), iatrogenic (induced by medical treatment) or
idiopathic (of unknown cause). Children with untreated PGHD will have
significant growth failure, potential adult heights significantly less than five
feet, and may have abnormal body composition with decreased bone mineralization,
decreased lean body mass, and increased fat mass.

The main therapeutic goal in PGHD is to restore growth and improve body
composition, enabling short children to achieve normal height and prevent
complications that could involve metabolic abnormalities, cognitive deficits and
reduced quality of life. The current standard of care for PGHD is limited to
daily subcutaneous injections of rhGH with a treatment cycle lasting up to an
average of seven years. Poor compliance with daily rhGH injections during
treatment can result in an adverse impact on growth and body composition. In
August 2021, the FDA approved a new treatment, Skytrofa, a once-weekly injection
that would reduce the number of injections over the course of treatment for a
patient; however, based on our market research, we believe that many providers
and patients will have a preference for an orally administered treatment, when

On March 18, 2020, we closed the business combination (the "Merger") among the
Company, formerly known as NewLink Genetics Corporation ("NewLink"), Cyclone
Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of NewLink, and Lumos
Pharma, Inc., ("Private Lumos") which has since been renamed "Lumos Pharma Sub,
Inc." whereby Merger Sub merged with and into Private Lumos, with Private Lumos
surviving as a wholly-owned subsidiary of the Company.

LUM-201 Growth hormone secretagogue

Our pipeline is focused on the development of an orally administered small
molecule, LUM-201, which is a growth hormone ("GH") secretagogue, also called
ibutamoren, for rare endocrine disorders where injectable recombinant human
growth hormone ("rhGH") is currently approved. LUM-201 is a tablet formulation
that will be administered once daily.

Lumos acquired LUM-201 from Ammonett Pharma LLC ("Ammonett") in July 2018.
LUM-201 received an Orphan Drug Designation ("ODD") in the United States and the
European Union for Growth Hormone Deficiency ("GHD") in 2017. The United States
patent "Detecting and Treating Growth Hormone Deficiency" has been issued with
an expiration in 2036. Related patents have been issued in the European Union,
Australia, Israel, Japan, South Korea, Hong Kong, and Ukraine with related
patent applications pending in multiple other jurisdictions. In November 2022,
we filed a patent application titled "Compactable

————————————————– ——————————

table of contents

Oral Formulations of Ibutamoren," which contains claims directed to certain
improved LUM-201 drug product formulations we intend to utilize in our Phase III
trial and ultimately commercialize. The novel formulation takes advantage of
unique properties of LUM-201 to provide a commercial product offering well
suited for the full range of potential patient preferences and will result in a
reduced treatment burden for the patient population. The application is
currently pending and if granted, would provide composition of matter protection
through November 2042 for the commercialized version of LUM-201.

If approved, LUM-201 has the potential to become the first approved oral GH
secretagogue to treat rare endocrine disorders associated with GH deficiencies,
starting with PGHD, providing an alternative to the current standard regimen of
recombinant growth hormone product injections. A secretagogue is a substance
that stimulates the secretion or release of another substance. LUM-201
stimulates the release of GH and is referred to as a GH secretagogue.

LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as
the ghrelin receptor, and also suppresses the release of somatostatin, thus
providing a differentiated mechanism of action to treat some rare endocrine
disorders (involving a deficiency of GH) by increasing the amplitude of
endogenous, pulsatile GH secretion. LUM-201's stimulatory effect is regulated by
both circulating levels of GH and its down-stream mediator insulin-like growth
factor ("IGF-1") which at supraphysiological levels feedbacks or negatively
regulates additional release of GH from the pituitary, hence protecting against
hyperstimulation of the pituitary.

The PGHD population consists of patients diagnosed with organic PGHD (a more
severe GH deficiency) and idiopathic PGHD (a less severe GH deficiency). LUM-201
has been observed to stimulate endogenous GH secretion in patients who have a
functional but reduced hypothalamic pituitary GH axis, also known as moderate or
idiopathic PGHD patients. We believe that patients with idiopathic PGHD (i.e.,
those who have a functional but reduced hypothalamic pituitary GH axis)
represent approximately 60% of PGHD patients and are expected to respond to

During the fourth quarter of 2020, we launched a program to study the effects of
LUM-201 in PGHD and initiated our Phase 2 clinical trial ("OraGrowtH210 Trial"
or the "Phase 2 Trial") with the opening of the initial sites participating in
this study. The OraGrowtH210 Trial is a global multi-site randomized study
evaluating orally administered LUM-201 at three dose levels (0.8, 1.6 and 3.2
mg/kg/day) against a standard dose of daily injectable rhGH in approximately 80
subjects diagnosed with idiopathic PGHD.

The primary endpoint of the study is preliminary validation of our predictive
enrichment marker ("PEM") patient selection strategy as evidenced by the
percentage of selected patients who grow in response to LUM-201. Each patient
enrolled in our Phase 2 clinical trials is given a single dose of LUM-201 at the
0.8 mg/kg/day dose to determine if they meet the cut-off criteria for
enrollment, which is a baseline IGF-1 > 30 ng/ml and stimulated GH ?5 ng/ml. The
primary efficacy endpoint is annualized height velocity ("AHV"). Secondary
endpoints include selection of a pediatric dose of LUM-201 for future studies
including Phase 3 and determination of the degree of repeatability of the PEM
selection process in PEM positive patients screened for participation in

We announced on February 28, 2023, that we completed enrollment for our
OraGrowtH210 Trial with 82 subjects and that we anticipate the complete set of
six-month annualized height velocity, primary outcome data on all 82 subjects in
the fourth quarter of 2023.

A second concurrent trial of LUM-201 in PGHD exploring the effects of the novel
mechanism of action of LUM-201 in amplifying the pulsatile secretion of growth
hormone (the "OraGrowtH212 Trial") was initiated in the second quarter of 2021.
The OraGrowtH212 Trial in PGHD is being run in parallel with the OraGrowtH210
Trial. The OraGrowtH212 Trial is a single site, open-label trial evaluating the
pharmacokinetic and pharmacodynamic ("PK/PD") effects of LUM-201 in up to 24
PGHD subjects at two different dose levels, 1.6 and 3.2 mg/kg/day. The objective
of the OraGrowtH212 Trial is to confirm prior clinical data illustrating the
increased pulsatile release of endogenous growth hormone unique to LUM-201 and
its potential for this mechanism of action to contribute to efficacy in PGHD.
Our OraGrowtH212 Trial is being conducted at a single specialized pediatric
center with the capacity to conduct the more frequent sample acquisition and
monitoring required for this type of clinical trial. Data from the OraGrowtH212
Trial may be supportive in future regulatory filings; however, this trial is not
required for regulatory approval of LUM-201. The primary endpoint for this trial
is six months of PK/PD and height velocity data in up to 24 subjects. As we
announced on February 28, 2023, we completed enrollment for this trial with 22
subjects and the primary data readout for all 22 subjects is anticipated in the
fourth quarter of 2023.

In May 2022, we announced that the OraGrowtH210 Trial had been extended to 24
months to allow subjects to continue LUM-201 therapy uninterrupted.
Additionally, during the second quarter of 2022, the protocol for the
OraGrowtH212 Trial was amended to allow treatment until subjects reach a bone
age of 14 for females and 16 for males, reflecting near-adult height.

————————————————– ——————————

table of contents

The extension of the treatment period will not impact the primary outcome data
read out for the OraGrowtH210 or OraGrowtH212 trials, which will be based on the
annualized data from the first six months of treatment. We do not anticipate
these protocol changes, on a stand-alone basis, will extend the time to the
initiation of our Phase 3 clinical trial.

During the first quarter of 2022, we initiated our OraGrowtH213 Trial (the
"OraGrowtH213 Trial," and together with the OraGrowtH210 Trial, the OraGrowtH211
Trial, and the OraGrowtH212 Trial, the "OraGrowtH Trials"), an open-label,
multi-center, Phase 2 study evaluating the growth effects and safety of LUM-201
following 12 months of daily rhGH in up to 20 idiopathic PGHD subjects who have
completed the OraGrowtH210 Trial. Subjects will be administered LUM-201 at a
dose level of 3.2 mg/kg/day for up to 12 months.

On November 14, 2022, we announced that our interim analyses for our
OraGrowtH210 and OraGrowtH212 Trials had met expectations. The interim analysis
for OraGrowtH210 was performed after 41 patients, randomized into four treatment
arms of approximately 10 patients, completed six months of treatment. The
six-month AHV on 1.6 mg/kg/day LUM-201 met our expectations for growth. The mean
(median) AHV at six months is shown below for each of the four treatment arms:

7.26 (7.71) cm/year in the 0.8 mg/kg group (n=11) 8.57 (8.61) cm/year in the 1.6 mg/kg group (n=10) 7.77 (8.11) cm/year 3.2 mg/kg arm (n=10) 11.05 (10.48) cm/year in rhGH arm (n=10)

The mean AHV of 8.6 cm/year at six months observed in the 1.6mg/kg dose arm was
in line with our expectations for 8.3 cm/year AHV, which was observed after 12
months of recombinant growth hormone (rhGH) treatment in a moderate
naïve-to-treatment PGHD patient population derived from the large 20-year Phase
4 Eli Lilly GeNeSIS database.1 This was also comparable to the first-year height
velocity observed for similar moderate PGHD subjects treated with rhGH in three
other large historical databases.2,3,4

The rhGH control arm produced an AHV of 11.05 cm at six months, an unexpected
growth response for the idiopathic PGHD population. We believe this unexpected
growth was likely due both to the presence of two of the youngest subjects in
the rhGH cohort, which showed a robust growth response (15.6 and 12.7 cm/yr),
growing at rates greatly above the 50th percentile for subjects this age, and
due to other imbalances in several baseline characteristics also documented as
predictors of greater growth response to rhGH.2,4,5 The higher than anticipated
AHV seen in this idiopathic PGHD population treated in the rhGH control arm was
inconsistent with multiple historical trials in similarly characterized
populations, which predicted growth in the 8.3-8.6 cm/year range.2-5 Baseline
characteristics other than age which are predictive of greater growth on therapy
include: height (shorter stature), lower height and IGF-1 standard deviation
scores (SDS), greater distance from mid-parental height (MPH), and higher body
mass index standard deviation score (BMI SDS). The imbalanced baseline
parameters of the 1.6 mg/kg LUM-201 arm compared to the rhGH arm are shown in
the table below.

An imbalance in the five baseline parameters predicts higher growth of the rhGH arm.

                                  1.6 mg LUM-201 Mean (SD)       rhGH
              Baseline metrics              N=10               Mean (SD)
            Age in months               99.3 (28.3)           90.3 (26.7)
            Height in cm                114.6 (9.6)          111.6 (11.9)
            IGF-1 SDS                   -1.17 (0.72)          -1.37 (0.48)
            MPH in cm                  166.98 (7.15)         168.78 (8.85)
            BMI SDS                     -0.35 (0.79)         +0.31 (1.05)

We believe the imbalance in age should even out as enrollment progresses since
age is a stratification factor. Two of the three subjects under five years are
in the rhGH cohort and are growth outliers, growing at rates greatly above the
50th percentile for subjects this age. With higher enrollment, we believe the
imbalance of predictors favoring faster growth in response to rhGH treatment in
the control arm is likely to resolve, resulting in greater balance across all

1 Blum et al JES 2021
2 Lechuga-Sancho et al JPEM 2009
3 Ranke et al JCEM 2010
4 Bright et al JES 2021
5 Yang et al Nature Sci Rep 2019

————————————————– ——————————

table of contents

With enrollment completed in our OraGrowtH210 Trial, there is greater balance in
the baseline parameters known to be predictive of higher growth between the 1.6
mg/kg/day arm and the rhGH arm.

The baseline characteristics in the fully enrolled cohorts, as shown below,
represent a better balance, which we anticipate will result in diminishing the
effect of outliers.

                                     LUM-201 1.6 mg        rhGH
                                        Mean (SD)        Mean (SD)
                                          N=22             N=20
                   Age (months)        95.2 (27.3)      91.4 (23.3)
                   Height (cm)        113.0 (11.0)     112.3 (10.5)
                   Height SDS          -2.42 (0.68)     -2.23 (0.41)
                   IGF-1 SDS           -1.40 (0.57)     -1.39 (0.47)
                   MPH (cm)            165.4 (7.4)     169.1 (8.26)
                   MPH SDS             1.69 (0.81)      1.91 (0.65)
                   BA Delay (yrs)       1.8 (0.9)        1.9 (0.9)
                   BMI SDS             -0.27 (0.90)     +0.01 (0.95)

OraGrowtH210 Interim Analysis Months 9 and 12 Highlights

The nine and twelve-month interim data available for a subset of the subjects
demonstrated the durability of the growth response for LUM-201 at these later
treatment intervals, albeit with a smaller number of patients. The decline in
the AHV rate for the rhGH arm was more pronounced over time (11.05 cm/yr at six
months to 9.93 cm/yr at 12 months) compared to the LUM-201 1.6 mg/kg arm (8.57
cm/yr at six months to 8.14 cm/yr at 12 months).

LUM-201 shows sustained growth over 12 months.

              OraGrowtH210 AHV (mean)      6 months       9 months       12 months
                                         cm/year   n    cm/year   n    cm/year    n
             0.8 mg/kg/day LUM-201        7.26     11    6.17     5     6.74      4
             1.6 mg/kg/day LUM-201        8.57     10    8.48     6     8.14      4
             3.2 mg/kg/day LUM-201        7.77     10    6.80     6     6.94      3
             34 ?g/kg/day rhGH            11.05    10    10.46    7     9.93      4

OraGrowtH212 Interim Analysis Highlights

The OraGrowtH212 Trial is a single site, open-label trial evaluating the
pharmacokinetic (PK) and pharmacodynamic (PD) effects of oral LUM-201 in up to
24 treatment-naïve PGHD subjects at two dose levels, 1.6 and 3.2 mg/kg/day.
Every subject in the OraGrowtH212 Trial was PEM-positive and, therefore,
enriched for responsiveness to LUM-201.

The interim analysis of the OraGrowtH212 Trial was performed after ten subjects
randomized to one of two LUM-201 treatment arms had completed six months of
treatment. The AHV for each arm was comparable to that observed in the
OraGrowtH210 Trial. The data also demonstrate the growth is durable out to 12
months, albeit in a more limited number of subjects. This separate study also
supports the narrowing of the AHV difference between LUM-201 and rhGH seen in
the OraGrowtH210 Trial as subjects approach 12 months on treatment.

————————————————– ——————————

table of contents

LUM-201 in GraGrowtH212 Demonstrates Comparable Growth Rates to OraGrowtH210:

                    OraGrowtH212          6 months       9 months       12 months
                                        cm/year   N    cm/year   n    cm/year    n
                1.6 mg/kg/day LUM-201    7.14     5     6.85     4     7.21      2
                3.2 mg/kg/day LUM-201    8.60     5     8.00     4     7.78      3

Additional data for the OraGrowtH212 Trial was presented on March 5, 2023 at the
International Meeting of Pediatric Endocrinology in an oral presentation. The
presentation included the results of analysis of 15 subjects, or five additional
subjects (three in the 1.6 mg/kg treatment arm and two in the 3.2 mg/kg
treatment arm) since the interim analysis. Results showed that across the dose
range of 1.6 to 3.2 mg/kg/day for six months, LUM-201 is well-tolerated and
produces dose-dependent and substantial increases in GH AUC0-12h. The
presentation showed that increased GH pulse amplitude was associated with
improved height velocity compared to baseline, and that effects on annualized
height velocity were durable through 12 months.

Post hoc analysis combining OraGrowtH210 and OraGrowtH212

In an effort to determine an optimal dose for a Phase 3 trial, a post-hoc
analysis was conducted, combining growth data from OraGrowtH210 and OraGrowtH212
Trials to increase the sample size. This analysis demonstrated comparable mean
AHVs at six, nine, twelve months between the two higher doses of LUM-201. While
there are some baseline characteristic differences between studies, all subjects
enrolled to date are PEM-positive and are, therefore, representative of the
broader moderate PGHD population. This post-hoc analysis of the combined 1.6
mg/kg and 3.2 mg/kg cohorts from both trials confirmed very similar growth rates
between the top two LUM-201 doses and supports the selection of 1.6 mg/kg as an
optimal dose for the Phase 3 trial. Based on historical research, we did not
expect a dose-response between 1.6 mg/kg and 3.2 mg/kg compared to 0.8 to 1.6
mg/kg based on the previously generated PK/PD data in normal healthy volunteers
that showed a PD plateau at 2.8 mg/kg.6

             OraGrowtH210 + OraGrowtH212     6 months       9 months       

12 months

                                           cm/year   N    cm/year   n    

cm/year n

            1.6 mg/kg/day LUM-201           8.09     15    7.83     10    7.83      6
            3.2 mg/kg/day LUM-201           8.05     15    7.28     10    7.36      6

Safety and Tolerability Highlights

We believe LUM-201 will demonstrate a favorable safety profile as data from both
OraGrowtH trials to date show comparable safety and tolerability to the rhGH
subjects in the trials. In the interim data, there were no treatment-related
Serious Adverse Events (SAEs), no drop-outs due to SAE's and no meaningful
safety signals observed in either laboratory values, adverse event data, or in
electrocardiogram values. The safety data for the OraGrowtH212 Trial is
consistent with the data in the OraGrowtH210 Trial.

6 Merck 001 test

————————————————– ——————————

table of contents

The figure below shows the clinical development plan for LUM-201.

                     [[Image Removed: Pipeline slide.jpg]]

Potential expansion of LUM-201 indications

In May 2022, we announced a clinical collaboration with Massachusetts General
Hospital ("MGH") to evaluate oral LUM-201 in nonalcoholic fatty liver disease
("NAFLD") in an investigator-initiated trial. This trial will evaluate a dose of
25 mg/day of LUM-201 in 10 men and women with NAFLD; this dose is supported by
the large Phase 2 database of treatment of adults with LUM-201 by Merck, showing
increases in growth hormone and IGF-1 from baseline through as long as 24
months, along with improvements in body composition. Enrollment in the trial has
begun and the first subject has been dosed. GH is a critical stimulator of
lipolysis, and preclinical data suggest that amplifying GH secretion has the
potential to reduce hepatic steatosis and prevent NAFLD progression. Enhancing
the natural pulsatile release of GH has been shown clinically in short-term
studies to be more efficacious in inducing lipolysis than continuous infusions
of GH. The primary endpoints will be to determine the changes in intrahepatic
lipid content, hepatic inflammation and fibrosis with GH augmentation as
measured by H-MRS and Perspectum's LiverMultiScan®. Biopsies will be conducted
on a subset of subjects to obtain additional information at the genetic and
cellular level in this indication.

We have approved an unsolicited grant application for this study and are providing LUM-201 for this pilot study. Lumos has pending application for a method-of-use patent for LUM-201 in NAFLD and retains his LUM-201 intellectual property rights in this indication.

We continue to explore our development path to expand into additional
indications for LUM-201. We are actively reviewing the mechanism of action of
LUM-201 in a subset of affected patients in other potential indications. Based
on our initial review to date, we have narrowed our focus for the next
indications to include Idiopathic Short Stature, with a focus on the Asia
markets, and Prader Willi Syndrome, where we see an attractive global
opportunity. We have prioritized our resources for PGHD and currently plan to
advance planning for Prader Willi Syndrome and Idiopathic Short Stature
indications subsequent to the data read-out for OraGrowtH210.

Ebola vaccine

In November 2014, NewLink entered into the NewLink Merck Agreement with Merck to
develop and potentially commercialize its Ebola vaccine rVSV?G-ZEBOV that it
licensed from PHAC. rVSV?G-ZEBOV was also eligible to receive a PRV if approval
was granted by the FDA, with the Company entitled to 60% of the PRV value
obtained through sale, transfer or other disposition of the PRV. On December 20,
2019, Merck announced that the FDA approved its application for ERVEBO® (Ebola
Zaire Vaccine, Live) for the prevention of disease caused by Zaire Ebola virus
in individuals 18 years of age and older. Pursuant to the asset purchase
agreement, Merck agreed, among other things, to pay us for the PRV in two
installments. As required by the agreement, Merck paid us $34.0 million on
September 1, 2020 and $26.0 million on January 11, 2021.

We have received and have the potential to continue to earn royalties on sales
of the vaccine in certain countries. However, we believe that the market for the
vaccine will be limited primarily to areas in the developing world that are

————————————————– ——————————

table of contents

from royalty payment or where the vaccine is donated or sold at low or no margin
and, therefore, we do not expect to receive material royalty payments from Merck
in the foreseeable future.

Oncology Candidates

We have three small-molecule product candidates, which we acquired from NewLink
in the merger. These product candidates include two indoleamine-2, 3-dioxygenase
pathway inhibitors, indoximod and NLG802 (a prodrug of indoximod), and one
direct IDO1 enzymatic inhibitor, NLG919.

Two U.S. patents covering both the salt and prodrug formulations of indoximod
were issued in the United States on August 15, 2017 and February 19, 2019,
respectively, providing exclusivity until at least 2036. We are continuing to
pursue international patent coverage for these formulations in some countries.
We may explore the potential for further development and licensing opportunities
for these product candidates; however, we currently do not have any active
program for these acquired small molecule product candidates.

Financial overview


We have no products approved for commercial sale and have not generated any
revenue from product sales. In the future, we may generate revenue from product
sales, or license fees, milestones, or other upfront payments if we enter into
any collaborations or license agreements. We may also continue to generate
revenue from royalties on product sales. We expect that our future revenue will
fluctuate from quarter to quarter for many reasons, including the uncertain
timing and amount of any such payments and sales.

R&D expenses

Research and development expenses consist primarily of costs incurred to advance
our product candidate, LUM-201. Our research and development expenses include
internal personnel expenditures along with external research and development
expenses incurred under arrangements with third parties, such as contract
research and manufacturing organizations, consultants, and our scientific

We expense research and development costs as incurred. Nonrefundable advance
payments for goods and services that will be used in future research and
development activities are capitalized as an asset and expensed when the service
has been performed or when the goods have been received. We expect our research
and development expenses to increase for the foreseeable future as we continue
to conduct our clinical trial programs for our product candidates develop our
pipeline and pursue regulatory approval of our product candidates.

General and administrative expenses

General and administrative expenses consist primarily of professional fees for
legal, auditing, tax and business consulting services, personnel expenses and
travel costs. We expect that general and administrative expenses will increase
in the future as we expand our operating activities.

Significant Accounting Policies and Significant Judgments and Estimates

We have prepared our condensed consolidated financial statements in accordance
with U.S. GAAP, which requires us to make estimates, assumptions and judgments
that affect the reported amount of assets, liabilities, expenses. On an ongoing
basis, we evaluate these estimates and judgments. We based our estimates on
historical experience and on various assumptions that we believe to be
reasonable under the circumstances. These estimates and assumptions form the
basis for making judgments about the carrying values of assets and liabilities
and the recording of expenses that are not readily apparent from other sources.
Actual results could, therefore, differ materially from these estimates under
different assumptions or conditions.

Management believes there have been no material changes to the critical
accounting policies from those discussed in "Note 2 - Summary of Significant
Accounting Policies and Recent Accounting Pronouncements" of our consolidated
financial statements included in our 2022 Annual Report.

————————————————– ——————————

table of contents

Investment performance

Ended 3-month comparison March 31, 2023 And in 2022:

                                                        Three Months Ended March 31,
                                                          2023                  2022                Change in $                 Change in %
                                                               (in thousands)                      (in thousands)
Royalty revenue                                    $           691          $      111                     580                             523  %
Total revenues                                                 691                 111
Operating expenses:
 Research and development                                    4,369               4,221                     148                               4  %
General and administrative                                   4,357               3,621                     736                              20  %
Total operating expenses                                     8,726               7,842

Other income, net                                              689                  11                     678                            6164  %

Net loss                                           $        (7,346)         $   (7,720)

Earnings.Increased revenue $600,000 3 months ended
March 31, 2023 Compared to the same period in 2022 due to royalties earned in connection with the sale of ERVEBO®.

Research and Development Expenses. Research and development expenses increased
by $0.1 million for the three months ended March 31, 2023 compared to the same
period in 2022 primarily due to increases of $0.5 million in clinical trial
expenses and $0.1 million in legal and consulting expenses, offset by a decrease
of $0.5 million in contract manufacturing expenses.

General and Administrative Expenses. General and administrative expenses
increased by $0.7 million for the three months ended March 31, 2023 compared to
the same period in 2022 primarily due to increases of $0.4 million in licensing
expenses, $0.1 million in personnel-related expenses and $0.2 million in travel

Other Income, net. Other income, net increased by $0.7 million for the three
months ended March 31, 2023 compared to the same period in 2022 primarily due to
an increase in interest income driven by an increase in interest rates and
short-term investments.

Liquidity and funding sources

We have historically devoted substantially all our efforts toward research and
development and have never earned revenue from commercial sales of our products.
We expect to continue to incur additional substantial losses in the foreseeable
future as a result of our research and development programs and from general and
administrative costs associated with our operations. However, we believe that
our existing cash, cash equivalents and short-term investment balance of
approximately $58.0 million as of March 31, 2023 will be sufficient to allow us
to fund our operations into the third quarter of 2024, inclusive of the primary
read out of the OraGrowtH210 and OraGrowtH212 Trials for patients with
idiopathic (moderate) PGHD and for at least 12 months from the filing date of
this Quarterly Report.

We may seek to sell additional equity or debt securities or obtain a credit
facility from time to time if our available cash and cash equivalents are
insufficient to satisfy our liquidity requirements or if we develop additional
opportunities to do so. The sale of additional equity or convertible debt
securities would result in additional ownership dilution to our stockholders. If
we raise additional funds through the issuance of debt securities or preferred
stock, these securities could have rights senior to those of our common stock
and could contain covenants that would restrict our operations. We may require
additional capital beyond our currently forecasted amounts. Any such required
additional capital may not be available on reasonable terms, if at all. If we
are unable to obtain additional financing, we may be required to reduce the
scope of, delay or eliminate some or all of our planned research and development
activities, which could harm our business.

Because of the numerous risks and uncertainties associated with the research and
development of our product candidates, we are unable to estimate the exact
amounts of our working capital requirements. Our future funding requirements
will depend on many factors, including, but not limited to:

————————————————– ——————————

table of contents

• Primary data analysis of a Phase 2 study expected to be released in Q4 2023.

• The extent, progress, results and costs of our product candidates’ clinical trials, as well as discovery and development activities related to new product candidates.

• The timing and associated costs of obtaining regulatory approval for our product candidates;

• costs of commercialization activities if any of our product candidates are approved for sale; This includes marketing, sales, equipment and distribution costs.

• The cost of manufacturing our product candidates and the products we commercialize;

• our ability to establish and maintain strategic collaborations, licensing or other arrangements, and the financial terms of such agreements;

• Whether and to what extent any outstanding loans provided by the government will need to be repaid.

•the costs involved in preparing, filing, prosecuting, maintaining, defending
and enforcing patent claims, including litigation costs and the outcome of such

•changes in domestic and global business or macro-economic conditions, including
any further adverse impacts from the COVID-19 pandemic or the military conflict
in Ukraine, resulting labor shortages, supply chain disruptions, and inflation;

• Timing, receipts and amounts of our future product sales or royalties, if any.

On December 30, 2020, we entered into a Controlled Equity OfferingSM Sales
Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co., as agent (the
"Agent"), pursuant to which we may offer and sell from time to time through the
Agent up to $50.0 million of shares of our common stock (the "Shares"). The
offering and sale of the Shares has been registered under the Securities Act.
Under the Sales Agreement, the Agent may sell the Shares by any method permitted
by law and deemed to be an "at-the-market" offering as defined in Rule 415(a)(4)
promulgated under the Securities Act, including sales made directly on or
through the Nasdaq, on any other existing trading market for the Shares, in
negotiated transactions at market prices prevailing at the time of sale or at
prices related to such prevailing market prices and/or any other method
permitted by law. We will notify the Agent of the number of Shares to be issued,
the time period during which sales are requested to be made, any limitation on
the number of Shares that may be sold in any one day and any minimum price below
which sales may not be made. We intend to use the net proceeds from this
offering for working capital and general corporate purposes, which include, but
are not limited to, expanding clinical development opportunities for our product
candidate into potential additional indications, and general and administrative
expenses. We may also use a portion of the net proceeds to invest in future
strategic transactions to expand and diversify our product pipeline through the
acquisition or licensing of product candidates or technologies that are
complementary to our own. We will pay the Agent a commission of up to 3.0% of
the gross sales price of the Shares sold through it under the Sales Agreement.
In addition, we have agreed to reimburse certain expenses incurred by the Agent
in connection with the offering. The Sales Agreement may be terminated by the
Agent or by us at any time upon notice to the other party, as set forth in the
Sales Agreement, or by the Agent at any time in certain circumstances, including
the occurrence of a material and adverse change in our business or financial
condition that makes it impractical or inadvisable to market the shares or to
enforce contracts for the sale of the Shares. As of March 31, 2023, no shares
had been issued under the Sales Agreement.

So long as our public float is less than $75 million, we will be subject to the
restrictions set forth in General Instruction I.B.6 to Form S-3, which limit our
ability to conduct primary offerings under a Form S-3 registration statement,
including with respect to issuances under our at-the-market program under the
Sales Agreement. Under such limitations, we may not sell, during any 12-month
period, securities on Form S-3 having an aggregate market value of more than
one-third of our public float. As of May 1, 2023, our public float calculated in
accordance with General Instruction I.B.6 of Form S-3 was $20.1 million.

On August 16, 2022, we announced that our board of directors had authorized a
share repurchase program, under which we may purchase up to $3.0 million shares
of our outstanding common stock. During the first quarter of 2023, we
repurchased 87,694 shares for approximately $305,000. All such purchases were
made through open-market transactions with such repurchased shares effectively
retired upon repurchase.

————————————————– ——————————

table of contents

Cash flow

The following table shows the primary sources of funds and uses of cash for each period shown below (in thousands).

                                                    Three Months Ended 

March 31st,

                                                         2023                    2022
   Net cash used in operating activities     $         (9,197)                $ (8,033)
   Net cash used in investing activities               (2,463)                       -
   Net cash used in financing activities                 (309)                     (18)
   Net decrease in cash and equivalents      $        (11,969)                $ (8,051)

For the three months ended March 31, 2023 and 2022, our operating activities
used cash of $9.2 million and $8.0 million, respectively. The increase in cash
used was primarily due to increases of $1.5 million in the change in working
capital and a $0.1 million decrease in adjustments to reconcile net loss to net
cash used in operating activities, offset by a decrease of $0.4 million in
losses from operations.

For the three months ended March 31, 2023 and 2022, our investing activities
used cash of $2.5 million and $0, respectively. The increase is due to $2.5
million of cash used for purchases of short-term investments during the three
months ended March 31, 2023.

For the three months ended March 31, 2023 and 2022, our financing activities
used net cash of $0.3 million and $18,000, respectively. The increase was
primarily due to $0.3 million in cash paid for common stock repurchases during
the three months ended March 31, 2023.

© Edgar Online, Source glance

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *